The pharmacological control of tumour angiogenesis, besides the use of specific monoclonal antibodies directed to vascular endothelial growth factor (VEGF) (see the above reported Avastin), can be controlled with tyrosine kinase inhibitors (TKIs, for example Sunitinib [6]) that block the signalling pathway that activates the angiogenic processes, and/or by the use of chemicals that interrupt the signalling between cells (for example Lenalidomide, the levo enantiomer of the old drug Thalidomide [7]). The gene discussed is VEGFA; the disease is neoplasm.